Soparkar Peter's Form 4 filing
Adverum Biotechnologies, Inc. (ADVM) · filed Dec 10, 2021
- Accession no.
- 0001209191-21-069098
- Filed
- Dec 10, 2021
- Trade date
- Dec 8, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $47.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Soparkar PeterCIK 0001736315 | Officer (See Remarks section) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2021 | Common Stock | PPurchaseAcquired | +25,000 | $1.91F1 | +$47,750 | 258,631 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.895 to $1.92. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Operating Officer and Chief Legal Officer